Giuliana Grossi

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.

Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.

During Suicide Prevention Month, UPMC experts discuss how lived experience, peer support, and connection strengthen suicide prevention.

Trial, transplant equity gaps in AML; Texas Medicaid funding dispute; pediatric GLP-1 access gaps; earlier biologic use; eye care restores vision.

The FDA expanded accelerated approval of sevabertinib to previously untreated HER2-mutant non-squamous NSCLC, citing a 75% response rate in trial data.

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.

Coordinated networks—not isolated referrals—drove social care success in North Carolina and Ballad Health, says Halima Ahmadi-Montecalvo, PhD, MPH.

gMG rescue therapy hinges on hospital access; grocery aid cuts diabetes complications; trials, CAR T strain oncology; myeloma faces logistics barriers.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.

Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options expanding treatment choice.

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.

DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

Policy makers should vet the methodology behind reported cost savings before trusting the numbers, says Halima Ahmadi-Montecalvo, PhD, MPH.

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Waist circumference (WC) predicts mortality risk in older adults independent of BMI, with high WC linked to 24% greater death risk, a new study finds.

Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.

ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.

Closed-loop referral systems confirm outcomes, not just referrals, avoiding false success and building durable, scalable social care infrastructure.

Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Bridget Keenan, MD, PhD, of UCSF, stresses close communication across clinical, industry, and lab teams to run safe CAR T-cell trials.